Baird lowered the firm’s price target on Alto Neuroscience (ANRO) to $10 from $32 and keeps an Outperform rating on the shares. The firm lowered its target on the ALTO-100 failure and they are rmeoving it from its model even though management indicated there are signals that support patient stratification.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANRO:
- Alto Neuroscience CEO says ‘strong cash balance to support us’
- Alto Neuroscience falls 47% after announcing ALTO-100 did not meet endpoint
- Alto Neuroscience’s Phase 2b study of ALTO-100 did not meet primary endpoint
- Alto Neuroscience falls -3.8%
- Four new option listings and one option delisting on September 18th